Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy

Heart

Volumn 93, Issue 6, 2007, Pages 708-710

  Melacini, P ^a,b   Maron, B J ^a,b   Bobbo, F ^a,b   Basso, C ^a,b   Tolcajuk, B ^a,b   Zucchetto, M ^a,b   Thiene, G ^a,b   Iliceto, S ^a,b  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; AMIODARONE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; PROPRANOLOL; SOTALOL; VERAPAMIL;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART ARREST; HEART DEATH; HEART PROTECTION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUDDEN DEATH; TREATMENT OUTCOME;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CARDIOMYOPATHY, HYPERTROPHIC; CHILD; CHILD, PRESCHOOL; DEATH, SUDDEN, CARDIAC; FEMALE; HUMANS; INFANT; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SOTALOL; VERAPAMIL;

EID: 34249279544     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.099416     Document Type: Article

References (14)

1. Maron BJ. Hypertrophic cardiomyopathy. JAMA 2002;287:1308-20.
2. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/ European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol, 2003;42:1687-713.
3. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death. Revisited in a large non-referral-based patient population. Circulation 2000;102:858- 64.
4. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-18.
5. Maron BJ, Shen W-K, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-73.
6. Jayatilleke I, Doolan A, Ingles J, et al. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. Am J Cardiol 2004;93:1192-4.
7. Maron BJ, Estes NAM III, Maron MS, et al. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 2003;107:2872-5.
8. Cecchi F, Olivotto I, Montereggi A, et al. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy assessment in an unselected non-referral based patient population. Heart 1998;79:331-6.
9. McKenna WJ, Oakley CM, Krikler DM, et al. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985;53:412-16.
10. Östman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose β-adrenoceptor antagonist treatment. J Am Coll Cardiol 1999;34:1813-22.
11. Maron BJ, Spirito P, Haas TS, for the ICD in HCM Investigators. Efficacy of the implantable defibrillator for prevention of sudden death in hypertrophic cardiomyopathy: data form the international registry of 506 high risk patients [abstract]. Circulation 2005;112(Suppl II):531.
12. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention in sudden death. Heart 2002;87:169-76.
13. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004;363:1881-91.
14. Pacifico A, Hohnlose SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. N Engl J Med, 1999;340, 1855-62.